Literature DB >> 19111058

Nucleophilic addition of organozinc reagents to 2-sulfonyl cyclic ethers: stereoselective synthesis of manassantins A and B.

Hyoungsu Kim1, Amanda C Kasper, Eui Jung Moon, Yongho Park, Ceshea M Wooten, Mark W Dewhirst, Jiyong Hong.   

Abstract

A convergent route to the synthesis of manassantins A and B, potent inhibitors of HIF-1, is described. Central to the synthesis is a stereoselective addition of an organozinc reagent to a 2-benzenesulfonyl cyclic ether to achieve the 2,3-cis-3,4-trans-4,5-cis-tetrahydrofuran of the natural products. Preliminary structure-activity relationships suggested that the (R)-configuration at C-7 and C-7''' is not critical for HIF-1 inhibition. In addition, the hydroxyl group at C-7 and C-7''' can be replaced with a carbonyl group without loss of activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19111058      PMCID: PMC2656112          DOI: 10.1021/ol8024617

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  17 in total

Review 1.  HIF-1 as a target for drug development.

Authors:  Amato Giaccia; Bronwyn G Siim; Randall S Johnson
Journal:  Nat Rev Drug Discov       Date:  2003-10       Impact factor: 84.694

2.  Using stereoelectronic effects to explain selective reactions of 4-substituted five-membered ring oxocarbenium ions.

Authors:  Deborah M Smith; K A Woerpel
Journal:  Org Lett       Date:  2004-06-10       Impact factor: 6.005

3.  Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1.

Authors:  Chowdhury Faiz Hossain; Yong-Pil Kim; Scott R Baerson; Lei Zhang; Richard K Bruick; Kaleem A Mohammed; Ameeta K Agarwal; Dale G Nagle; Yu-Dong Zhou
Journal:  Biochem Biophys Res Commun       Date:  2005-08-05       Impact factor: 3.575

4.  Regulation of HIF-1alpha stability through S-nitrosylation.

Authors:  Fang Li; Pierre Sonveaux; Zahid N Rabbani; Shanling Liu; Bin Yan; Qian Huang; Zeljko Vujaskovic; Mark W Dewhirst; Chuan-Yuan Li
Journal:  Mol Cell       Date:  2007-04-13       Impact factor: 17.970

5.  Total synthesis of guanacastepene a: a route to enantiomeric control.

Authors:  Mihirbaran Mandal; Heedong Yun; Gregory B Dudley; Songnian Lin; Derek S Tan; Samuel J Danishefsky
Journal:  J Org Chem       Date:  2005-12-23       Impact factor: 4.354

6.  Stereoselective synthesis of tetrahydrofuran lignans via BF(3) x OEt(2)-promoted reductive deoxygenation/epimerization of cyclic hemiketal: synthesis of (-)-odoratisol C, (-)-futokadsurin A, (-)-veraguensin, (+)-fragransin A(2), (+)-galbelgin, and (+)-talaumidin.

Authors:  Hyoungsu Kim; Ceshea M Wooten; Yongho Park; Jiyong Hong
Journal:  Org Lett       Date:  2007-09-01       Impact factor: 6.005

Review 7.  The potential role of intrinsic hypoxia markers as prognostic variables in cancer.

Authors:  Eui Jung Moon; David M Brizel; Jen-Tsan Ashley Chi; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2007-08       Impact factor: 8.401

8.  Efficient methods for the preparation of alkyl-aryl and symmetrical or unsymmetrical dialkyl ethers between alcohols and phenols or two alcohols by oxidation-reduction condensation.

Authors:  Taichi Shintou; Teruaki Mukaiyama
Journal:  J Am Chem Soc       Date:  2004-06-16       Impact factor: 15.419

Review 9.  Evaluation of HIF-1 inhibitors as anticancer agents.

Authors:  Gregg L Semenza
Journal:  Drug Discov Today       Date:  2007-09-18       Impact factor: 7.851

10.  Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1.

Authors:  Tyler W Hodges; Chowdhury Faiz Hossain; Yong-Pil Kim; Yu-Dong Zhou; Dale G Nagle
Journal:  J Nat Prod       Date:  2004-05       Impact factor: 4.050

View more
  7 in total

1.  False-positive rate determination of protein target discovery using a covalent modification- and mass spectrometry-based proteomics platform.

Authors:  Erin C Strickland; M Ariel Geer; Jiyong Hong; Michael C Fitzgerald
Journal:  J Am Soc Mass Spectrom       Date:  2013-10-10       Impact factor: 3.109

2.  Discovery of Manassantin A Protein Targets Using Large-Scale Protein Folding and Stability Measurements.

Authors:  M Ariel Geer Wallace; Do-Yeon Kwon; Douglas H Weitzel; Chen-Ting Lee; Tesia N Stephenson; Jen-Tsan Chi; Robert A Mook; Mark W Dewhirst; Jiyong Hong; Michael C Fitzgerald
Journal:  J Proteome Res       Date:  2016-07-08       Impact factor: 4.466

3.  Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.

Authors:  Hidemitsu Minegishi; Shinji Fukashiro; Hyun Seung Ban; Hiroyuki Nakamura
Journal:  ACS Med Chem Lett       Date:  2013-01-27       Impact factor: 4.345

4.  Exploring a sulfone linker utilizing trimethyl aluminum as a cleavage reagent: solid-phase synthesis of sulfonamides and ureas.

Authors:  Tsai-Wen Chung; Chih-Hau Chen; Chu-Chung Lin; Hsien-Jen Wu; Chung-Ming Sun; Wen-Sheng Chung
Journal:  Mol Divers       Date:  2012-06-30       Impact factor: 2.943

5.  Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations.

Authors:  Amanda C Kasper; Eui Jung Moon; Xiangqian Hu; Yongho Park; Ceshea M Wooten; Hyoungsu Kim; Weitao Yang; Mark W Dewhirst; Jiyong Hong
Journal:  Bioorg Med Chem Lett       Date:  2009-04-22       Impact factor: 2.823

6.  Synthesis and Biological Evaluation of Manassantin Analogues for Hypoxia-Inducible Factor 1α Inhibition.

Authors:  Do-Yeon Kwon; Hye Eun Lee; Douglas H Weitzel; Kyunghye Park; Sun Hee Lee; Chen-Ting Lee; Tesia N Stephenson; Hyeri Park; Michael C Fitzgerald; Jen-Tsan Chi; Robert A Mook; Mark W Dewhirst; You Mie Lee; Jiyong Hong
Journal:  J Med Chem       Date:  2015-09-22       Impact factor: 7.446

7.  Total Synthesis, Stereochemical Assignment, and Divergent Enantioselective Enzymatic Recognition of Larreatricin.

Authors:  Harry J Martin; Ioannis Kampatsikas; Rik Oost; Matthias Pretzler; Emir Al-Sayed; Alexander Roller; Gerald Giester; Annette Rompel; Nuno Maulide
Journal:  Chemistry       Date:  2018-10-01       Impact factor: 5.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.